br Pipeline and Commercial Insight: Obesity - the 11 billion market that never was br br The obesity market is easily characterized as attractive, featuring a booming patient potential needing long term therapy, but repeated product withdrawals and failed pipeline candidates highlight the reality of increasingly cautious regulatory bodies, reluctant payers, and a clinical community that puts more stock in diet and exercise: $513.7m sales in 2008 fall far short of analyst predictions. ( AND rt=Pipeline-and-Commercial-Insight-Obesity-the-11-billion-market-that-never-was.